Evidence map›Paper›PMID 35145510›Full record

ArticleFrontiers in immunology2021

Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.

Chao Xia, Wei Huang, Yun-Liang Chen, Hai-Bin Fu, Ming Tang, Tao-Lan Zhang, Jing Li, Guo-Hua Lv, Yi-Guo Yan, Zhi-Hua Ouyang and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Chao XiaThe First Affiliated Hospital, Health Management Center, Hengyang Medical School, University of South China, Hengyang, China.
Wei HuangThe First Affiliated Hospital, Health Management Center, Hengyang Medical School, University of South China, Hengyang, China.
Yun-Liang ChenShenzhen Audaque Data Technology Co., Ltd., Shenzhen, China.
Hai-Bin FuDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Ming TangDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Tao-Lan ZhangDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Jing LiDepartment of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Guo-Hua LvDepartment of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Yi-Guo YanDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Zhi-Hua OuyangDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Nvzhao YaoDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Cheng WangDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Ming-Xiang ZouDepartment of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
University of South China · CNCentral South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immunotherapy only achieves efficacy in some cancer patients, and less is known about other immune checkpoint molecules in chordoma. Here, we aimed to determine the expression of PD-L1, HHLA2, B7H3, IDO-1 and Galectin-9 in spinal chordoma and evaluated their association with tumor infiltrating lymphocytes (TILs), clinicopathological characteristics and survival of patients. Methods: Using multiplexed quantitative immunofluorescence (QIF), we simultaneously measured the levels of five different immune checkpoint molecules and major TIL subsets in 92 human spinal chordoma samples. Results: Tumor HHLA2 and PD-L1 were positive in 80.0% and 86.0% of cases, respectively. However, B7H3, IDO-1 and Galectin-9 positivity on tumor cells were only seen in 21.0% of cases, despite all showing predominantly stromal expression. Coexpression of these QIF markers in the tumor compartment was scarcely detected except for PD-L1 and HHLA2, which was observed in 69.6% of cases. While tumoral HHLA2 and stromal B7H3 expressions were associated with an aggressive tumor phenotype, suppressive immune response (specifically including elevated PD-1 Conclusion: These data provide a better understanding of the immunosuppressive mechanism in chordoma and may be useful for the development of combination or novel immunotherapy approaches aiming to improve therapeutic efficacy and survival.

Indexed as

B7-H1 AntigenBiomarkers, TumorChordomaFemaleFluorescent Antibody TechniqueHumansImmunoglobulinsKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMagnetic Resonance ImagingMaleMiddle AgedPrognosisSpinal NeoplasmsTomography, X-Ray ComputedB7-H1 AntigenBiomarkers, TumorCD274 protein, humanHHLA2 protein, humanImmunoglobulinsHHLA2immune checkpoint moleculesPD-L1quantitative immunofluorescencespinal chordomatumor infiltrating lymphocytes

Identifiers

PMID35145510
PMCPMC8824251
OpenAlexW4210310037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.